Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
MX2012001244A
Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system.
WO2010055148A2
Dosage of oligonucleotides suitable for the treatment of tumors
JP2008247909A
Method for inhibiting "melanoma inhibitory activity" (mia)
EP1935428A1
Oligonucleotide-polymer conjugates
AU2005218759A1
Pharmaceutical composition
AU2004299670A1
Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
WO2005014812A2
An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia
EP1568383A2
Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US7963956B2
Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
WO03064457A1
A method for inhibiting 'melanoma inhibitory activity' mia
